Wouter Latour Net Worth

The estimated Net Worth of Wouter Latour is at least 2.95 百万$ dollars as of 6 May 2021. Wouter Latour owns over 200,000 units of Vaxart Inc stock worth over 94,000$ and over the last 7 years he sold VXRT stock worth over 2,106,671$. In addition, he makes 747,711$ as Chairman of the Board at Vaxart Inc.

Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!

Sign up

Already have an account? Sign in

Wouter Latour VXRT stock SEC Form 4 insiders trading

Wouter has made over 4 trades of the Vaxart Inc stock since 2019, according to the Form 4 filled with the SEC. Most recently he exercised 200,000 units of VXRT stock worth 340,000$ on 6 May 2021.

The largest trade he's ever made was selling 333,334 units of Vaxart Inc stock on 23 November 2020 worth over 2,106,671$. On average, Wouter trades about 94,445 units every 65 days since 2018. As of 6 May 2021 he still owns at least 100,000 units of Vaxart Inc stock.

You can see the complete history of Wouter Latour stock trades at the bottom of the page.

Wouter Latour biography

Dr. Wouter W. Latour M.D. serves as Chairman of the Board of the Company. He has served as the President and Chief Executive Officer of Vaxart, Inc. From September 2011 to the closing of the Merger, Dr. Latour served as Private Vaxart’s President and Chief Executive Officer and from October 2011 to the closing of the Merger, Dr. Latour served as a member of Private Vaxart’s board of directors. From June 2011 to September 2011, Dr. Latour served as Private Vaxart’s Chief Operating Officer. From June 2009 until joining Private Vaxart, Dr. Latour was an independent consultant to life sciences companies. From January 2005 to May 2009, Dr. Latour was the Chief Executive Officer and a member of the board of directors of Trinity Biosystems, Inc., a biopharmaceutical company. Prior to these roles, Dr. Latour held numerous executive positions at various pharmaceutical and biotechnology companies. Dr. Latour received an M.D. from the University of Amsterdam and an M.B.A. from Stanford University.

What is the salary of Wouter Latour?

As the Chairman of the Board of Vaxart Inc, the total compensation of Wouter Latour at Vaxart Inc is 747,711$. There are no executives at Vaxart Inc getting paid more.

How old is Wouter Latour?

Wouter Latour is 61, he's been the Chairman of the Board of Vaxart Inc since 2020. There are 4 older and 8 younger executives at Vaxart Inc. The oldest executive at Vaxart Inc is Anne VanLent, 72, who is the Independent Director.

What's Wouter Latour's mailing address?

Wouter's mailing address filed with the SEC is C/O VAXART, INC., 170 HARBOR WAY, SUITE 300, SOUTH SAN FRANCISCO, CA, 94080.

Insiders trading at Vaxart Inc

Over the last 7 years, insiders at Vaxart Inc have traded over 322,706,538$ worth of Vaxart Inc stock and bought 8,979,091 units worth 2,899,807$ . The most active insiders traders include Capital, Llc Armistice Capi...、Steven Lo、Wouter Latour. On average, Vaxart Inc executives and independent directors trade stock every 57 days with the average trade being worth of 1,309,363$. The most recent stock trade was executed by W. Mark Watson on 18 June 2024, trading 20,000 units of VXRT stock currently worth 13,600$.

What does Vaxart Inc do?

since its founding in 2004, vaxart has pursued a vision of advancing vaccines—to make them as tablets rather than injections. the company’s proprietary oral vaccine delivery platform is suitable to deliver any recombinant vaccine, positioning vaxart to introduce oral forms of multiple vaccines in the rapidly growing global vaccines market.

Complete history of Wouter Latour stock trades at Vaxart Inc

Vaxart Inc executives and stock owners

Vaxart Inc executives and other stock owners filed with the SEC include:

• Wouter Latour,
  Chairman of the Board
• Cezar Andrei Floroiu M.B.A.,
  CEO, Pres, Principal Financial Officer & Director
• Dr. Sean N. Tucker,
  Sr. VP & Chief Scientific Officer
• Margaret A. Echerd,
  Sr. VP & Principal Accounting Officer
• Sean Tucker,
  Chief Scientific Officer
• Margaret Echerd,
  Principal Accounting Officer, Vice President, Controller
• Anne VanLent,
  Independent Director
• Michael Finney,
  Independent Director
• Robert Yedid,
  Lead Independent Director
• Todd Davis,
  Independent Director
• Karen Wilson,
  Independent Director
• Keith Maher,
  Director
• Steven Boyd,
  Director
• Andrei Floroiu,
  Chief Executive Officer, Principal Financial Officer, Director
• Edward B. Berg,
  Sr. VP & Gen. Counsel
• John M. Harland M.B.A., CPA,
  Consultant
• Dr. James F. Cummings M.D.,
  Chief Medical Officer
• Dr. Rajesh Kapoor Ph.D.,
  Sr. VP of Quality
• Dr. Richard M. Schwartz,
  Sr. VP of Technical Operations
• Brant Biehn,
  Sr. VP of Bus. Operations
• Shaily Jaini Garg,
  Sr. VP of Clinical Devel. & Project Management
• Julie M Cherrington,
  Director
• Edward B Berg,
  SVP, General Counsel
• John M Harland,
  Chief Financial Officer
• Richard J Markham,
  Director
• Geoffrey F Cox,
  Director
• John P Richard,
  Director
• Phillip E Lee,
  Chief Financial Officer
• David E. Wheadon,
  Director
• James F. Cummings,
  Chief Medical Officer
• W. Mark Watson,
  Director
• Elaine J Heron,
  Director
• Steven Lo,
  President, Chief Exec Officer
• Fuad Ahmad,
  Interim CFO